AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:liquid Route of administration: oral
Study NCT04357002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: patients will be given a single bolus IV injection of 15 mg/kg of tranexamic acid (TXA) 20 minutes before surgical incision plus one vaginal placebo tablet 60 minutes before skin incision.
Study NCT04357002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal dinoprostone
Description: patients will be given one vaginal dinoprostone tablet (3mg) 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study NCT04357002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: patients will be given one vaginal placebo tablet 60 minutes before skin incision and a normal saline IV bolus 20 minutes before surgical incision
Study NCT01899144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study NCT01899144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study NCT03804034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Block of resin
Study NCT03804034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire
Study NCT02851186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT02851186 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study NCT04337385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interrupting 3 hours of prolonged sitting with high intensity interval exercise
Description: Breaking up a prolonged bout of sitting in adolescents using high intensity interval exercise
Study NCT04337385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 hours of prolonged sitting
Description: Participants will be asked to remain seated for 3 hours and refrain from moving their lower limbs
Study NCT03224546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Subjects will receive payments for providing cocaine negative urine samples.
Study NCT03461510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp
Description: Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at \~250 mg/dL during fMRI.
Study NCT03461510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic Euglycemic clamp
Description: Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
Study NCT04140136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienols
Description: Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
Study NCT04140136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
Study NCT01776385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
Study NCT01776385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
Study NCT04639115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod
Study NCT03020290 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment for PAD during medical care (SuperA stent (Abbott))
Description: Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
Study NCT02776371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified non-clarithromycin triple therapy
Description: H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
Study NCT02776371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential therapy
Description: H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
Study NCT00785967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Various vaccines
Description: VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
Study NCT00785967 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Various vaccines
Description: VAQTA: 1.0ml IM at weeks 24 \& 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
Study NCT04490031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: patient in Ketamine group will be given Ketamine as sedative agent
Study NCT00553865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Study NCT00553865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Study NCT00553865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OJP-2028
Description: Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Study NCT01328171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Panitumumab
Description: irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT01328171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT04798807 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nutritional screening
Study NCT03930160 — intervention group
Intervention type: OTHER
Intervention: Logistic Organ Dysfunction System Score
Description: Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
Study NCT02884843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation laryngeal Tube Suction
Description: Intubation laryngeal Tube Suction
Study NCT02884843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuraGain Laryngeal Mask
Description: AuraGain Laryngeal Mask
Study NCT00589485 — intervention group
Intervention type: DEVICE
Intervention: Simplex® Bone Cement
Description: This arm will utilize Simplex® Bone Cement in total knee replacement.
Study NCT00589485 — intervention group
Intervention type: DEVICE
Intervention: Cobalt™ Bone Cement
Description: This arm utilizes Cobalt™ Bone Cement in total knee replacement.
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:liquid Route of administration: oral
Study NCT03728127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian cardioprotective diet
Description: Brazilian cardioprotective diet prescription
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT03728127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brazilian cardioprotective diet plus 30g/day of mixed nuts
Description: Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine* [Recombinant] *as applicable
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT01067638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
Study NCT01347684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy, splint therapy and physical therapy
Description: Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
Study NCT01347684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care using current drugs
Description: Standard Drug therapy
Study NCT03366649 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Undersizing Mitral Annuloplasty
Description: Participants will receive a commercially available annuloplasty ring of the surgeon's choice. Sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size.
Study NCT03366649 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Papillary Muscle Approximation
Description: One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
Study NCT00939796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acclarent Tympanostomy Tube Delivery System
Description: A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
Study NCT01676220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Description: HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]).
Study NCT01746602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timoptic® 0.5%
Description: Timoptic® 0.5% Eye Drops, Merck, single instillation
Study NCT01676220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Description: Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Study NCT03869996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fast track care protocol
Description: fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
Study NCT03869996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care protocol
Description: standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
Study NCT04147260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: Film-coated tablet
Study NCT04147260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match BI 730357
Description: Film-coated tablet
Study NCT04147260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Film-coated tablet
Study NCT01555021 — intervention group
Intervention type: GENETIC
Intervention: Genotyping assays
Description: Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood.
Study NCT03706911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500A-LAI
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Study NCT01880554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contrast-enhanced intraoperative ultrasound
Description: Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages
Study NCT01734382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants \< 30 kg) or 8 mg/kg (for participants >/=30 kg) Q2W/Q3W/Q4W.
Study NCT03119571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial CCL admission
Description: Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
Study NCT03119571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial ICU admission
Description: Evaluate for additional testing and/or procedures
Study NCT01746602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timophtal sine® 0.5%
Description: Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
Study NCT01746602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genteal HA®
Description: Genteal HA® Eye Drops, Novartis, single instillation
Study NCT01746602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hylo-Comod®
Description: Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
Study NCT01746602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz®
Description: Thealoz® Eye Drops, Thea, France, single instillation
Study NCT03127787 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMV Assay
Description: Molecular diagnostic test to detect CMV
Study NCT03549507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Study NCT02945787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spanish-Language Version of the Stop Smoking for Good
Description: Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
Study NCT02945787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI-Produced Spanish-language Self-help Booklet
Description: Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet.
Study NCT00906997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical fecal occult blood test
Description: Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
Study NCT00906997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Every 10 years, with sedation.
Study NCT03194490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined intervention group
Description: The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
Study NCT03194490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The standard intervention
Description: The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral .
Study NCT04086875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participate in focus group
Study NCT04086875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages
Study NCT04086875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT04086875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04086875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00880165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure apparatus
Description: Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
Study NCT01473927 — intervention group
Intervention type: OTHER
Intervention: Endoscopy
Description: Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
Study NCT05547022 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular revascularisation
Description: Peripheral vascular angioplasty or stenting
Study NCT03457233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
Study NCT03457233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH antagonist
Description: cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
Study NCT03457233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin Chorimon
Description: 10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm